
Opinion|Videos|February 19, 2025
Use of RNA-Based Molecular Panels in Metastatic NSCLC
Panelists discuss the use of RNA-based molecular panels in metastatic non–-small cell lung cancer (NSCLC), highlighting their role in guiding personalized treatment decisions and improving patient outcomes.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















